AMD supplements increase smokers' risk of cancer

Article

Smokers with age-related macular degeneration (AMD) should not be taking the age-related eye disease study (AREDS) formulation of vitamins and antioxidants, as it puts them at an increased risk of developing lung cancer, according to a presentation given at the Retina Subspecialty Day of this year's AAO congress in New Orleans, US.

Smokers with age-related macular degeneration (AMD) should not be taking the age-related eye disease study (AREDS) formulation of vitamins and antioxidants, as it puts them at an increased risk of developing lung cancer, according to a presentation given at the Retina Subspecialty Day of this year's AAO congress in New Orleans, US.

Emily Chew from the National Eye Institute, USA outlined which patients should and should not take AREDS supplements. The AREDS study enrolled 4,700 subjects to receive supplements of vitamin C and E, beta carotene, zinc and copper and were followed for an average of 6.3 years.

While a protective benefit was seen in patients with large bilateral macular drusen and advanced AMD in one eye, there was no protective benefit for patients with mild and moderate AMD. Patients who smoke, or who have given up smoking within the past year, should avoid the supplements altogether because of an increased risk of cancer.

For most individuals, however, the benefits of the supplements appear to outweigh any risks and Dr Chew concluded that this supplementation regimen could prevent 300,000 people over the next five years from developing advanced macular degeneration or experiencing significant loss of vision as a result of progressive disease.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.